PharmaNews
Oncol Res Treat 2022;45:230 –233 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - April 4, 2022 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2022;45:228 –229 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - April 4, 2022 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2022;45:227 –227 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - April 4, 2022 Category: Cancer & Oncology Source Type: research
Incidence, Prevalence, and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population-Representative German Claims Data Analysis
This study therefore aimed to analyze the use of different TKIs used in 1st- and 2nd-line treatment and the frequency of TKI switches in CML.Methods: This observational study was based on the InGef research database, an anonymized representative claims dataset in Germany (n = 4 million). An incidence and prevalence patient CML cohort was followed for 5 and 3 years. Analyses regarding incidence, prevalence, and therapy distribution were performed descriptively.Results: 151 patients were included in the incidence and 636 patients in the prevalence cohort. This resulted in an incidence of 1.8 (95% confidence interval [CI]: 1....
Source: Oncology Research and Treatment - March 25, 2022 Category: Cancer & Oncology Source Type: research
Incidence, Prevalence and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population Representative German Claims Data Analysis
This study therefore aimed to analyze the use of different TKIs used in 1st- and 2nd-line treatment and the frequency of TKI switches in CML.
Methods
This observational study was based on the InGef research database, an anonymized representative claims dataset in Germany (n= 4 million). An incidence and prevalence patient CML cohort was followed for 5 and 3 years. Analyses regarding incidence, prevalence and therapy distribution were pe rformed descriptively.
Results
151 patients were included in the incidence and 636 patients in the prevalence cohort. This resulted in an incidence of 1.8 (95%-confidence interval [CI]:...
Source: Oncology Research and Treatment - March 25, 2022 Category: Cancer & Oncology Source Type: research
Sociodemographic, Clinical, Lifestyle and Psychological Correlates of Peripheral Neuropathy among 2 –12-Year Colorectal Cancer Survivors
Conclusions
In multivariable analyses, PN is affected by receiving chemotherapy, aging, sex, co-morbidities, stress-related factors and HRQoL in CRC survivors. Future PN-related studies can include these factors, and they can be examined in longitudinal studies to gain more knowledge about chronicity and severity of PN. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - March 18, 2022 Category: Cancer & Oncology Source Type: research
Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small-Cell Lung Cancer Patients with Chronic Infection
Conclusions: The PD-1 inhibitor showed an acceptable toxicity profile and moderate efficacy on NSCLC patients with chronic infection, but still has the potential to increase the incidence of hepatitis. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - March 1, 2022 Category: Cancer & Oncology Source Type: research
Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small Cell Lung Cancer Patients with Chronic Infection
Conclusions
The PD-1 inhibitor showed an acceptable toxicity profile and moderate efficacy on NSCLC patients with chronic infection, but still has the potential to increase the incidence of hepatitis. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - March 1, 2022 Category: Cancer & Oncology Source Type: research
A Panel of Three Serum MicroRNAs as a Potential Diagnostic Biomarker for Urothelial Carcinoma
OBJECTIVE: Urothelial carcinoma (UCa) is one of the most common malignancies of the genitourinary system, and early diagnosis is vital in improving the survival of UCa patients. Now, new effective non-invasive markers are urgently needed for the diagnosis of UCa. The present study aims to identify miRNAs for UCa diagnosis.
MATERIALS AND METHODS: We enrolled a total of 152 UCa patients and 135 normal controls at a single institution between 2012 to 2020. The expression levels of candidate miRNAs of all the subjects were calculated from serum samples based on quantitative reverse transcription-polymerase chain reaction (qRT...
Source: Oncology Research and Treatment - March 1, 2022 Category: Cancer & Oncology Source Type: research
Society Bulletins
Oncol Res Treat 2022;45:145 –155 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 28, 2022 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2022;45:140 –144 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 28, 2022 Category: Cancer & Oncology Source Type: research
Polypharmazie - Wechselwirkungen der BTKi
Oncol Res Treat 2022;45:138 –139 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 28, 2022 Category: Cancer & Oncology Source Type: research
Therapiemanagement von Sacituzumab Govitecan
Oncol Res Treat 2022;45:I –VIII (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 28, 2022 Category: Cancer & Oncology Source Type: research
Scalp Cooling for Prevention of Chemotherapy-Induced Alopecia for Women and Men with Various Cancer Entities: A Two-Years Survey of an Outpatient Cancer Center in Germany
Introduction: the aim of this survey was to assess the efficacy and the feasibility of scalp cooling in an outpatient hematological and oncological center in a real-world setting.
Methods: we prospectively monitored cancer patients from august 2017 to october 2019 receiving oncological treatments with scalp cooling, using the sensor-controlled system „DigniCap“. Effectiveness was defined by a self-estimated hair loss (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 25, 2022 Category: Cancer & Oncology Source Type: research
Clonal Evolution in Patients with Hormone Receptor Positive, HER-2 Negative Breast Cancer Treated with Chemotherapy or CDK4/6 Inhibitors
Conclusion: Clonal evolution might differ significantly between metastatic breast cancer patients with hormone receptor positive and HER-2 negative disease treated with chemo or CDK4/6 inhibitors. These results should be confirmed in larger patient cohorts. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 25, 2022 Category: Cancer & Oncology Source Type: research
